Celltrion Launches Autoimmune Disease Treatment In US
Celltrion, a major South Korean biopharmaceutical firm, on Thursday said it has launched its biosimilar product for Stelara, a ...
TMCnet2d
Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
Research and development expenses were $21.8 million for the quarter ended December 31, 2024, compared to $11.6 million for the same period in 2023. The increase of $10.2 million was primarily driven ...
Pulmonology Advisor4d
Silent Rhinovirus Infection Prevalent in Nasal Tissues
Silent rhinovirus (RV) infection is prevalent in nasal tissues and is associated with distinct immune responses in those with and without chronic rhinosinusitis with nasal polyps (CRSwNP). These were ...
Clinical Advisor4d
FDA to Review Depemokimab for Asthma With Eosinophilic Phenotype, CRSwNP
The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...
Taiwan News5d
U.S. FDA approves Celltrion's OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®
OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for interchangeability was supported by positive phase III data demonstrating comparable ...
The Pharma Letter5d
The week in pharma: action, reaction and insight – week to March 7
Last week’s significant research news included positive new Phase III data on Tezspire in nasal polyps from Amgen and ...